Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 29

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis63Systemic lupus erythematosus63Psoriatic arthropathy46Myasthenia gravis44Systemic scleroderma40Sjogren's syndrome31Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis16Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+307

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Medical device site joint infection

Recruiting

Study on the Effects of Rifampicin, Amoxicillin, and Moxifloxacin in Treating Prosthetic Joint Infections Caused by Cutibacterium acnes for Affected Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Nice

Duchenne muscular dystrophy

Recruiting

Study of Microdystrophin (GNT0004) Gene Therapy for Duchenne Muscular Dystrophy in Boys Who Can Walk

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Eculizumab
  • Sponsor:Genethon

Study on Ravulizumab for Children Aged 6 to 17 with Generalized Myasthenia Gravis

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Myasthenia gravis

Recruiting

Study on Nipocalimab for Children Aged 2-17 with Generalized Myasthenia Gravis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Bone disorder

Recruiting

Study on Treating Adynamic Bone Disorder with Teriparatide in Patients with Chronic Kidney Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Teriparatide
  • Sponsor:Region Hovedstaden

Osteoporosis

Recruiting

Study on the Use of Romosozumab and Zoledronic Acid for Treating Osteoporosis in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Romosozumab
  • Sponsor:Region Midtjylland

Axial spondyloarthritis+4

Recruiting

Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Leiomyosarcoma+1

Recruiting

Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

Registered drugNo placebo
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Synovial sarcoma+2

Recruiting

Study of Personalized Peptide Vaccine with PERVI-FUS, PERVI-NEO, and 11902A for Children and Young Adults with Metastatic Fusion-Driven Sarcomas

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Pervi-Fus
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Juvenile spondyloarthritis+2

Recruiting

Study on the Safety and Body Processing of Bimekizumab in Children with Juvenile Idiopathic Arthritis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Restless legs syndrome

Recruiting

Study on the Effects of Ferric Derisomaltose and Dopaminergic Therapy for Patients with Restless Legs Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Medizinische Universitaet Innsbruck

Malignant fibrous histiocytoma+3

Recruiting

Study of Pembrolizumab and Cabozantinib for Patients with Advanced Sarcomas: Undifferentiated Pleomorphic Sarcoma, Osteosarcoma, and Ewing Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Bergonie

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate26 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.